Conference Banner


Day 1
Day 2
PDF Download 
Hotel & Travel 
Press Pass 
Request Brochure 


Second Annual
Enabling Point-of-Care Diagnostics
August 19-20, 2008


Future of Cancer Diagnostics:
Next Generation Molecular Technology

August 21-22, 2008

 Science AAAS

Bio-IT World

The Scientist

Bio World Today




Systems Integration in Biodefense



Barbara McQuiston DARPA Technology Programs in Biodefense:
A Strategic Technology View

Ms. Barbara McQuiston, Director of the Strategic Technology Office (STO), Defense Advanced Research Projects Agency (DARPA)




undefinedAlbert Churilla, Ph.D., J.D., Chief, Medical S & T, Chem/Bio Technologies Directorate, Defense Threat Reduction Agency





Joseph Palma Systems Biology in Medical Development
Joseph M. Palma, MD, MPH, CPE, Senior Medical Advisor, USA Medical Research & Materiel Command




Analysis of the Department of Homeland Security’s Detect-to-Protect (D2P) Biological Sensor Field Tests
Michael Finnin, Research Staff Member, Institute for Defense Analyses

Bradley Smith Building an Effective Partnership between the Private Sector and Government for Biodefense Countermeasure Development
Bradley T. Smith, Ph.D., Assistant Professor, Center for Biosecurity, University of Pittsburgh Medical Center




Technology Challenges in Biological Threat Characterization
J. Patrick Fitch J. Patrick Fitch, Ph.D., Laboratory Director, National Biodefense Analysis and Countermeasures Center, Managed and Operated for DHS by BNBI, President, Battelle National Biodefense Institute, LLC (BNBI)




At this year’s Systems Integration in Biodefense meeting, we will hear from industry leaders about their strategy for meeting the needs of the community and bridging the technology gaps that still exist. New assays will be introduced that are highly multiplexed, integrated and field deployable. Technology developments in sample prep, signal transduction and amplification will be showcased, and specific examples of integrated systems will be presented. Dual-use application is an essential feature for products to have utility in biodefense and clinical settings. A discussion on getting products to market and facing commercialization, collaboration, and business challenges will be addressed. The meeting will be followed by the 2nd Annual Enabling Point-of-Care Diagnostics to elucidate the transition from biodefense to a clinical setting, and the tactical issues of implementation.

Scientific Advisory Board
Steven Buchsbaum, Ph.D., Senior Program Officer, Global Health Technologies, Bill & Melinda Gates Foundation
John C. Carrano, Ph.D., Vice President, Research and Development, Luminex Corporation
Kenton L. Lohman, Ph.D., Senior Biotechnology Advisor, Midwest Research Institute, National Capital Region Division
Lloyd J. Whitman, Ph.D., Deputy Director, Center for Nanoscale Science and Technology, National Institute of Standards and Technology



Second Annual Enabling Point-of-Care Diagnostics
August 19-20, 2008


Inaugural Future of Cancer Diagnostics: Next Generation Molecular Technologies
August 21-22, 2008

By Series:
By Region: